Related references
Note: Only part of the references are listed.Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research
Berthold Hocher et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
Hari Hendarto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists
Tomoki Kosugi et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Renal protection in diabetes: lessons from ONTARGET (R)
Eberhard Ritz et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus
Xiaoxiang Yan et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Adenosine A1 receptor antagonists in clinical research and development
Berthold Hocher
KIDNEY INTERNATIONAL (2010)
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
David J. Grieve et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure
Veselin Mitrovic et al.
CIRCULATION-HEART FAILURE (2009)
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
E. U. Graefe-Mody et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Mouse Models of Diabetic Nephropathy
Frank C. Brosius et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Vascular Calcification: The Killer of Patients with Chronic Kidney Disease
Masahide Mizobuchi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
S. Huettner et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and-786T>C gene variants with diabetic nephropathy
Intissar Ezzidi et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy
Frank C. Brosius
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice
Yukiko Kanetsuna et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy
Takahiko Nakagawa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line
S Senkel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2005)
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals -: The Framingham heart study
J Ärnlöv et al.
CIRCULATION (2005)
A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress
D Del Rio et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2005)
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes
KAM Jandeleit-Dahm et al.
JOURNAL OF HYPERTENSION (2005)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
D de Zeeuw et al.
KIDNEY INTERNATIONAL (2004)
Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis
B Hocher et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Proteinuria and the risk of developing end-stage renal disease
K Iseki et al.
KIDNEY INTERNATIONAL (2003)
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
T Nagakura et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide
BA Veldman et al.
JOURNAL OF HYPERTENSION (2002)
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population
HL Hillege et al.
CIRCULATION (2002)
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB
ML Onozato et al.
KIDNEY INTERNATIONAL (2002)
Angiotensin II type 1 receptor blockers
M Burnier
CIRCULATION (2001)
Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism
A Zanchi et al.
KIDNEY INTERNATIONAL (2000)
A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study
Y Higashi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
